期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 59, 期 6, 页码 3656-3659出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.05024-14
关键词
-
资金
- Cerexa, Inc.
- Achaogen
- Actelion
- Affinium
- American Proficiency Institute (API)
- AmpliPhi Biosciences
- Anacor
- Astellas
- AstraZeneca
- Basilea
- BioVersys
- Cardeas
- Cempra
- Cubist
- Daiichi Sankyo
- Dipexium
- Durata
- Exela
- Fedora
- Furiex
- Genentech
- GlaxoSmithKline
- Janssen
- Johnson Johnson
- Medpace
- Meiji Seika Kaisha
- Melinta
- Merck
- MethylGene
- Nabriva
- Nanosphere
- Novartis
- Pfizer
- Polyphor
- Rempex
- Roche
- Seachaid
- Shionogi
- Synthes
- Medicines Co.
- Theravance
- Thermo Fisher
- VenatoRx
- Vertex
- Waterloo
- Wockhardt
- Forest Laboratories, Inc.
Pseudomonas aeruginosa isolates (n = 3,902) from 75 U.S. medical centers were tested against ceftazidime-avibactam and comparator agents by the reference broth microdilution method. Overall, 96.9% of the strains were susceptible (MIC, <= 8 mu g/ml) to ceftazidime-avibactam, while the rates of susceptibility for ceftazidime, meropenem, and piperacillin-tazobactam were 83.8, 81.9, and 78.5%, respectively. Multidrug-resistant and extensively drug-resistant phenotypes were observed in 14.9 and 8.7% of the strains, respectively, and 81.0 and 73.7% of the strains were susceptible to ceftazidime-avibactam, respectively.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据